Moneycontrol
Last Updated : Apr 17, 2018 12:58 PM IST | Source: Moneycontrol.com

Glenmark Pharma Q4 PAT may dip 27.7% YoY to Rs. 173.7 cr: Edelweiss

Net Sales are expected to decrease by 8.5 percent Y-o-Y (up 2 percent Q-o-Q) to Rs. 2,247.6 crore, according to Edelweiss.

Moneycontrol News @moneycontrolcom
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Edelweiss has come out with its fourth quarter (Jan-March’ 18) earnings estimates for the Pharma sector. The brokerage house expects Glenmark Pharma to report net profit at Rs. 173.7 crore up 27.7% year-on-year (up 65.9% quarter-on-quarter).


Net Sales are expected to decrease by 8.5 percent Y-o-Y (up 2 percent Q-o-Q) to Rs. 2,247.6 crore, according to Edelweiss.


Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to fall by 28.5 percent Y-o-Y (down 1.7 percent Q-o-Q) to Rs. 317.2 crore.


Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

First Published on Apr 16, 2018 06:07 pm
Loading...
Sections
Follow us on
Available On